Literature DB >> 32555501

Conglobatins B-E: cytotoxic analogues of the C2-symmetric macrodiolide conglobatin.

Heather J Lacey1,2, Thomas J Booth3, Daniel Vuong4, Peter J Rutledge5, Ernest Lacey4,6, Yit-Heng Chooi3, Andrew M Piggott6.   

Abstract

Chemical investigation of a previously unreported indigenous Australian Streptomyces strain MST-91080 has identified six novel analogues related to the oxazole-pendanted macrodiolide, conglobatin. Phylogenetic analysis of the 16S rRNA gene sequence identified MST-91080 as a species of Streptomyces, distinct from reported conglobatin producer, Streptomyces conglobatus ATCC 31005. Conglobatins B-E diverge from conglobatin through differing patterns of methylation on the macrodiolide skeleton. The altered methyl positions suggest a deviation from the published biosynthetic pathway, which proposed three successive methylmalonyl-CoA extender unit additions to the conglobatin monomer. Conglobatins B1, C1 and C2 exhibited more potent cytotoxic activity selectively against the NS-1 myeloma cell line (IC50 0.084, 1.05 and 0.45 µg ml-1, respectively) compared with conglobatin (IC50 1.39 µg ml-1).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32555501     DOI: 10.1038/s41429-020-0332-3

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  3 in total

1.  Natural Occurrence of Hybrid Polyketides from Two Distinct Biosynthetic Pathways in Streptomyces pactum.

Authors:  Wei Zhou; Priyapan Posri; Taifo Mahmud
Journal:  ACS Chem Biol       Date:  2021-02-08       Impact factor: 5.100

2.  Modulation of Specialized Metabolite Production in Genetically Engineered Streptomyces pactum.

Authors:  Zhiran Ju; Wei Zhou; Hattan A Alharbi; Daniel C Howell; Taifo Mahmud
Journal:  ACS Chem Biol       Date:  2021-11-01       Impact factor: 5.100

Review 3.  Recently Discovered Secondary Metabolites from Streptomyces Species.

Authors:  Heather J Lacey; Peter J Rutledge
Journal:  Molecules       Date:  2022-01-28       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.